Evidence map›Paper›PMID 42700735›Full record

ArticleTranslational oncology2026

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.

Maria Antonietta De Ioris, Francesca Del Bufalo, Concetta Quintarelli, Valentina Bertaina, Francesco Fabozzi, Maria Giuseppina Cefalo, Iside Alessi, Chiara Grimaldi, Maria Felicia Villani, Maria Luisa D'Andrea and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Maria Antonietta De IorisPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: mantonietta.deioris@opbg.net.
Francesca Del BufaloPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Concetta QuintarelliPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Valentina BertainaPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Francesco FabozziPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Giuseppina CefaloPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Iside AlessiPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Chiara GrimaldiSurgical Oncology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Felicia VillaniNuclear Medicine Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Luisa D'AndreaRadiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Alessandra StracuzziPathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Claudio AltiniPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Carmen MalaspinaRadiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Matilde SinibaldiPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Stefano Di CeccaPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Laura IaffaldanoPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Clelia GeraciPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Marco BecilliPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Biagio De AngelisPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Alessandro CrocoliSurgical Oncology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Giulia CassanelliRadiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Stefano MargaritoraThoracic Surgery, Catholic University of the Sacred Heart, Rome, Italy.
Angela MastronuzziPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
Franco LocatelliPediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrognosis of Relapsed/Refractory (R/R) neuroblastoma is still dismal. Chemoimmunotherapy has been reported to improve the response rate. PATIENTS AND

methodsDinutuximab beta added to chemotherapy was used in an off-label setting. Treatment was administered on a 21-day schedule: on day 1 Irinotecan was administered at the dose of 50 mg/m

resultsTwenty-five children received chemo-immunotherapy. Hematological toxicity was the most common adverse event. The best overall response rate (ORR) was 52% (95% CI:31-72), with an ORR of 62% (95% CI: 38-82) at metastatic sites. Responses were higher at bone and bone marrow sites (ORR 67% and 92%, respectively). SIOPEN skeletal score declined during treatment, the best response being observed after the first 2/3 courses. Primary tumors and soft-tissue lesions were less responsive, though metabolic activity often decreased. Negative or low GD2 expression was observed in 10% and in 35% of tumor tissue, respectively at baseline and after treatment, with mean GD2-positive tumor cells decreasing from 88% to 62% in tumor tissue, mainly associated with differentiating histology. DISCUSSION: This real-world experience confirms that a short schedule is a feasible and effective option in R/R neuroblastoma. The dynamic and heterogeneous expression of GD2 deserves further evaluation, particularly in relation to selection of patients and subsequent GD2-directed treatment strategies.

Indexed as

Chemo-immunotherapyDinutuximab betaNeuroblastomaTarget therapy

Identifiers

PMID42700735
PMCPMC13679618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.